U.S. Glucagon Delivery Devices Market Summary

The U.S. glucagon delivery devices market size was estimated at USD 446.98 million in 2023 and is projected to grow at a CAGR of 8.33% from 2024 to 2030. There are several factors contributing to the market growth in the U.S., which include the growing prevalence of diabetes in the country, the development of advanced and user-friendly delivery devices, aging population, and increasing awareness about advantages of glucagon among patients and healthcare professionals.

According to the American Diabetes Association, around 38.4 million people in the U.S., accounting for around 11.6% of the population, had diabetes in 2021. Moreover, around 1.2 million people in the country are diagnosed with diabetes every year. As the number of individuals diagnosed with diabetes continues to increase, the incidence of hypoglycemia, a condition in which blood glucose levels drop, is also anticipated to rise. This condition is especially common among those on insulin therapy or certain oral medications, which are prescribed to manage blood sugar.

Key Market Trends & Insights

• The injectable devices segment held 47.6% of the U.S. market share in 2023, accounting for the largest proportion in the market. The accuracy and proven efficacy of injectable glucagon among healthcare providers and patients have solidified its position as a trusted delivery device.
• The retail pharmacies segment held 51.7% of the market share in 2023, accounting for the largest proportion of the market due to their widespread accessibility and consumer convenience. Retail pharmacies are often the first point of contact for patients seeking medical supplies and prescription medications, including glucagon delivery devices.
• The hospitals & clinics segment accounted for the largest market share of 40.6% in 2023. In hospitals and clinics, glucagon is frequently administered to patients experiencing hypoglycemic episodes, especially in emergency departments and inpatient units where immediate medical intervention is necessary.

Order a free sample PDF of the U.S. Glucagon Delivery Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 446.98 million
• 2030 Projected Market Size: USD 781.07 million
• CAGR (2024 - 2030): 8.33%

Key Companies & Market Share Insights

Key players in the glucagon delivery devices market in the U.S. include Eli Lilly and Company, Novo Nordisk A/SXeris Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and others. These players are focusing on enhancing their product offerings through product upgrades, strategic collaborations, and merger and acquisition activities to hold a prominent share of the market.

Key Players

• Eli Lilly and Company
• Novo Nordisk A/S
• Xeris Pharmaceuticals, Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Tandem Diabetes Care, Inc.
• Fresenius Kabi USA, LLC.
• Zealand Pharma A/S
• Amphastar Pharmaceuticals, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. glucagon delivery devices market is expected to experience consistent growth over the forecast period, supported by the increasing prevalence of diabetes, rising risk of hypoglycemia, and the adoption of user-friendly, advanced drug delivery solutions. The strong presence of injectable devices and the accessibility of glucagon through retail pharmacies are enhancing patient reach and treatment adherence. Hospitals and clinics remain critical end-use settings where immediate glucagon administration is required, strengthening demand. With increasing patient awareness, technological innovation, and healthcare support, the market is anticipated to expand steadily, ensuring better outcomes for diabetic patients nationwide.